Compare BRLT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRLT | FEMY |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 21.9M |
| IPO Year | 2021 | 2021 |
| Metric | BRLT | FEMY |
|---|---|---|
| Price | $1.25 | $5.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $1.70 | ★ $5.50 |
| AVG Volume (30 Days) | 75.1K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,483,000.00 | $2,293,313.00 |
| Revenue This Year | $6.72 | $105.16 |
| Revenue Next Year | $4.95 | $200.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.63 | ★ 40.77 |
| 52 Week Low | $1.11 | $0.29 |
| 52 Week High | $3.10 | $1.11 |
| Indicator | BRLT | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 97.17 |
| Support Level | $1.11 | $0.47 |
| Resistance Level | $1.37 | N/A |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.00 | 0.31 |
| Stochastic Oscillator | 52.00 | 83.92 |
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.